Blood Podcast cover image

Pembrolizumab plus AVD for classical Hodgkin lymphoma, targeting the CD40/CD40-ligand axis in Waldenström Macroglobulinemia, and CXCR4-expressing CAR-cytokine induced killer cells in AML

Blood Podcast

00:00

The Safety and Effectiveness of PD-1 Blockade for Hodgkin Lymphoma

Treatment with concurrent pembrolysumab and AVD shows promising safety and efficacy, but may yield spurious PET findings in some patients. Clerants of CTDNA after cycle 2 was associated with superior progression-free survival. None of the four patients who had persistent disease according to PET at the end of treatment, but negative CTDNA, have relapsed to date.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app